What is IgGenix?
IgGenix operates at the intersection of advanced immunology and drug discovery. The company specializes in the development of first-in-class antibodies designed to intercept the allergic cascade at its source. Its lead candidate, IGNX001, represents a significant advancement in therapeutic options for food allergies, targeting both pediatric and adult populations. By utilizing the SEQ SIFTER platform, IgGenix identifies and optimizes antibodies with high precision, allowing for a more targeted approach to complex immunological conditions. The firm's market position is defined by its commitment to rigorous clinical validation and its ability to bridge the gap between foundational research and scalable therapeutic solutions.
How much funding has IgGenix raised?
IgGenix has raised a total of $65M across 2 funding rounds:
Series A
$25M
Series B
$40M
Series A (2021): $25M with participation from AllerFund, ShangBay Capital, Alexandria Venture Investments, Khosla Ventures, and Matthias Westman
Series B (2023): $40M led by Khosla Ventures and Eli Lilly and Company Pvt
Key Investors in IgGenix
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, focusing on areas including health, AI, and sustainable energy.
Eli Lilly and Company Pvt
A subsidiary of the global biopharmaceutical giant, this firm specializes in developing advanced treatment options for chronic diseases and medical health innovations.
ShangBay Capital
ShangBay Capital is a venture capital firm based in Palo Alto that specializes in medical devices, biotechnology, and early-stage healthcare investments.
What's next for IgGenix?
With the recent influx of capital, IgGenix is poised to scale its clinical trial operations and expand its pipeline of allergy-focused therapeutics. The strategic focus will likely center on the advancement of IGNX001 through critical regulatory milestones, while simultaneously exploring the broader application of the SEQ SIFTER platform for other immunological disorders. As the company matures, the emphasis will shift toward establishing commercial partnerships and refining manufacturing processes to ensure the successful delivery of its innovative products to global markets. This phase of development is essential for validating the long-term efficacy of their antibody-based interventions and securing a dominant position in the competitive biopharmaceutical sector.
See full IgGenix company page
